Pulmonary Arterial Hypertension Articles & Analysis
5 articles found
Up to one-third of acute PE patients experience post-PE syndrome, such as chronic pulmonary hypertension (CTEPH) and chronic thromboembolic disease (CTED), which can be extremely disabling. ...
Up to 35% to 50% of patients with PE who are treated with anticoagulation therapy alone, experience post-PE syndrome, chronic thromboembolic disease (CTED) and chronic thromboembolic pulmonary hypertension (CTEPH). In addition, up to one third of these patients are readmitted to the hospital within the first ten years post treatment. ...
Vectorious Medical Technologies today announced that the FDA has granted breakthrough device designation for the company’s left atrial pressure (LAP) monitoring device. The V-LAP system is the first digital, wireless, battery-free device that can communicate from deep within the body using high-resolution waveform morphology, according to the Tel Aviv-based startup. Because the pressure of ...
Forbes recently featured Auris in an article about Johnson & Johnson's $3.5 billion all-cash acquisition of the company. In the deal, Auris is also eligible to receive up to $2.35 billion in additional milestone payments. This deal will boost J&J's plan to expand its robotics program. Auris was joined in 2007 by one of the pioneers of the robotic surgery, Dr. Fred Moll and since then ...
The use of a novel implantable string subcutaneous defibrillator (ISSD, Newpace) that has no can, and has been designed to be placed without the need for a surgical pocket, may allow improved patient compliance and aesthetics, is less invasive, and has optimal implantation time. The results from a first-in-man feasibility study on subcutaneous defibrillation utilising an integrated flexible ...